Trials / Terminated
TerminatedNCT04232878
A Single Ascending Dose Trial of CVL-936 in Healthy Subjects
A Phase 1, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Ascending Doses of CVL-936 In Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Cerevel Therapeutics, LLC · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVL-936 | CVL-936 |
| DRUG | Matching Placebo | Placebo matching CVL-936 |
Timeline
- Start date
- 2019-12-16
- Primary completion
- 2020-03-06
- Completion
- 2020-05-21
- First posted
- 2020-01-18
- Last updated
- 2020-06-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04232878. Inclusion in this directory is not an endorsement.